
Opinion|Videos|August 21, 2024
Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis
Dr Mahmoudjafari shares clinical strategies for optimizing patient outcomes and reducing the rate of adverse events and treatment discontinuations.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- At what point is it recommended for a patient's treatment regimen to change?
- What are some considerations for continuing or altering treatment regimens in myelofibrosis?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5




















